Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 3/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.35 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23782795 | 0.86 | HTR6 (0.45) | MAP2K4ELANEGABRG2GABRB3GABRA5 | |
| SCHEMBL30501085 | 0.86 | HTR6 (0.45) | MAP2K4ELANEGABRG2GABRB3GABRA5 | |
| SCHEMBL660243 | 0.85 | MAP2K4 (0.45) | MAP2K4NR1H2ELANEHSP90AB1CHEK1 | |
| SCHEMBL24148157 | 0.85 | ELANE (0.44) | MAP2K4ELANE | |
| SCHEMBL3517327 | 0.84 | MAP2K4 (0.44) | MAP2K4NR1H2ELANEHSP90AB1CHEK1 | |
| SCHEMBL3514381 | 0.83 | MAP2K4 (0.43) | MAP2K4NR1H2ELANEHSP90AB1CHEK1 | |
| SCHEMBL12194054 | 0.82 | ELANE (0.49) | MAP2K4NR1H2ELANEGABRG2GABRB3 | |
| SCHEMBL15081301 | 0.81 | MAP2K4 (0.44) | MAP2K4NR1H2ELANEHSP90AB1CHEK1 | |
| SCHEMBL5005856 | 0.81 | ELANE (0.48) | MAP2K4ELANECNR1ACHECNR2 | |
| SCHEMBL4006762 | 0.79 | MAP2K4 (0.58) | MAP2K4NR1H2ELANESMARCA2SMARCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465726-B2 | Substituted pyrrolo[2.3-B]pyridines | OSI PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465726-B2 | Substituted pyrrolo[2.3-B]pyridines | OSI PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465726-B2 | Substituted pyrrolo[2.3-B]pyridines | OSI PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| EP-1797054-A2 | ARYL-AMINO SUBSTITUTED PYRROLOPYRIMIDINE MULTI-KINASE INHIBITING COMPOUNDS | OSI Pharmaceuticals, Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20060211678-A1 | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006017443-A2 | ARYL-AMINO SUBSTITUTED PYRROLOPYRIMIDINE MULTI-KINASE INHIBITING COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211678-A1 | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | BMX, ERBB2, FRK | MAP2K4 58/4885NR1H2 2546/4885ELANE 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.